Comprehensive medication guide to Mycophenolic Acid including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$20 co-pay for generic mycophenolate mofetil on most commercial plans (Tier 1–2); Medicare Part B covers it for eligible kidney transplant patients with standard 20% cost-sharing; Medicare Part D places generic at Tier 2 and brand Myfortic at Tier 4. Prior authorization is commonly required by both Medicare and commercial plans.
Estimated Cash Pricing
$18–$28 for generic mycophenolate mofetil (CellCept generic) with GoodRx at most pharmacies; as low as $40–$42 for generic mycophenolate sodium (Myfortic generic) with GoodRx. Brand retail prices run $380–$900 without discounts for a 30-day supply.
Medfinder Findability Score
72/100
Summarize with AI
On this page
Mycophenolic acid (MPA) is an immunosuppressant medication used to prevent organ rejection after transplantation. It is available in two main forms in the United States: Myfortic (mycophenolate sodium), an enteric-coated delayed-release tablet, and as the active metabolite of mycophenolate mofetil (CellCept), a prodrug that converts to MPA in the body. Both are approved for kidney transplant rejection prevention; CellCept is additionally approved for heart and liver transplants.
Mycophenolic acid was initially discovered in 1893 and approved for medical use in the United States in 1995. It is classified as a selective immunosuppressant and antimetabolite, belonging to the IMPDH inhibitor class. Beyond transplantation, it is widely used off-label for autoimmune conditions including lupus nephritis, IgA nephropathy, vasculitis, pemphigus vulgaris, and pulmonary fibrosis.
Generic versions of both mycophenolate mofetil and mycophenolate sodium are widely available, manufactured by companies including Teva, Sandoz, Hikma, Accord, Ascend, and Mylan (Viatris). A newly approved ready-to-use oral suspension (Myhibbin, by Azurity Pharmaceuticals) was approved by the FDA in 2024 for pediatric and adult patients.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Mycophenolic acid works by reversibly inhibiting the enzyme inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the de novo synthesis of guanosine nucleotides (purines). By blocking this pathway, MPA depletes the supply of DNA building blocks that T and B lymphocytes need to proliferate and mount an immune attack on the transplanted organ.
The selectivity of mycophenolic acid for lymphocytes is what makes it particularly valuable: T and B cells rely heavily on de novo purine synthesis when activated, whereas most other cell types can compensate via an alternative salvage pathway. Additionally, MPA is fivefold more potent against the Type II isoform of IMPDH expressed in activated lymphocytes versus the Type I isoform expressed in most other cells. This selective cytostatic effect suppresses cell-mediated immune responses and antibody formation while sparing most other tissues.
Because IMPDH inhibition is reversible, twice-daily dosing is necessary to maintain continuous lymphocyte suppression. Skipping doses allows IMPDH activity to recover, creating windows of reduced immunosuppression that can trigger rejection in transplant recipients. Mycophenolate mofetil (CellCept) is a prodrug that is rapidly hydrolyzed to MPA in the body; mycophenolate sodium (Myfortic) delivers the sodium salt of MPA directly via an enteric-coated formulation that delays absorption until the intestine.
180 mg — delayed-release tablet (mycophenolate sodium / Myfortic)
Enteric-coated tablet; typical adult kidney transplant dose is four tablets (720 mg) twice daily
360 mg — delayed-release tablet (mycophenolate sodium / Myfortic)
Enteric-coated tablet; typical adult kidney transplant dose is two tablets (720 mg) twice daily
250 mg — capsule (mycophenolate mofetil / CellCept)
Standard capsule; typical kidney transplant dose is four capsules (1,000 mg) twice daily
500 mg — tablet (mycophenolate mofetil / CellCept)
Film-coated tablet; typical kidney transplant dose is two tablets (1,000 mg) twice daily; heart/liver dose is three tablets (1,500 mg) twice daily
200 mg/mL — oral suspension (mycophenolate mofetil)
Liquid formulation for patients unable to swallow tablets; available as Myhibbin (ready-to-use) or as powder for reconstitution
Generic mycophenolate mofetil (CellCept generic) is generally widely available in 2026 with no active FDA-declared nationwide shortage. Multiple manufacturers produce this formulation, providing supply redundancy. However, mycophenolate sodium delayed-release tablets (Myfortic generic) have a more limited manufacturer base and have experienced intermittent ASHP-tracked shortages from certain producers in past years. Individual pharmacies may occasionally run out of stock regardless of the national availability picture.
Because mycophenolate is classified as a specialty medication, not all retail pharmacies stock it in sufficient quantities. Specialty pharmacies that serve transplant patient populations typically maintain more consistent supply. If your pharmacy is out of stock, medfinder calls pharmacies near you to identify which ones have your specific formulation and strength in stock, then texts you the results—eliminating the need to call pharmacy after pharmacy yourself.
The FDA prescribing information states that mycophenolate must be prescribed only by physicians experienced in immunosuppressive therapy and management of organ transplant patients. Mycophenolic acid is not a controlled substance, so no special DEA registration is required. However, the FDA REMS program for mycophenolate requires specific counseling and pregnancy testing for patients of reproductive potential.
Prescribers who commonly manage mycophenolic acid therapy include:
Transplant Surgeons — initiate immunosuppression regimens post-transplant
Transplant Nephrologists — manage long-term immunosuppression for kidney transplant recipients
Transplant Hepatologists — manage liver transplant recipients
Transplant Cardiologists — manage heart transplant recipients
Rheumatologists — prescribe for off-label autoimmune uses (lupus nephritis, vasculitis, etc.)
Dermatologists — prescribe for autoimmune skin conditions (pemphigus vulgaris, bullous pemphigoid)
Nurse Practitioners (NPs) and Physician Assistants (PAs) — may prescribe within transplant or specialty programs under physician oversight per state law
Telehealth options are increasingly available for stable, established transplant patients for follow-up appointments. Transplant centers that participated in telehealth expansion during COVID-19 may offer virtual visits for routine monitoring. For new patients or those requiring initial evaluation, in-person visits remain the standard of care.
No. Mycophenolic acid (Myfortic), mycophenolate mofetil (CellCept), and mycophenolate sodium are not classified as controlled substances under the DEA Controlled Substances Act. There are no special DEA prescriber registration requirements, no mandatory Prescription Drug Monitoring Program (PDMP) reporting, and no limits on days' supply imposed by controlled substance regulations.
However, mycophenolate products are subject to an FDA Risk Evaluation and Mitigation Strategy (REMS) due to the risk of embryofetal toxicity. The REMS requires prescribers to counsel patients of reproductive potential about pregnancy prevention, conduct pregnancy testing before and during therapy, and advise on the use of two forms of contraception during treatment and for at least 6 weeks after stopping. The Mycophenolate Pregnancy Registry (1-800-617-8191) is available for patients who become pregnant during therapy. Additionally, the FDA prescribing information states that mycophenolate must be prescribed only by physicians experienced in immunosuppressive therapy and management of organ transplant patients.
The most common side effects are gastrointestinal and include:
Diarrhea, nausea, vomiting, stomach pain
Constipation and gas
Headache, tremor, dizziness, insomnia
Infections (UTIs, herpes/shingles, upper respiratory)
Anemia and leukopenia (low blood cell counts)
High blood pressure, swelling of ankles/feet
Progressive Multifocal Leukoencephalopathy (PML): Rare but life-threatening brain infection; symptoms include speech, vision, or muscle movement problems
Lymphoma and skin cancer: Increased risk due to immunosuppression (FDA boxed warning)
Serious infections: Including CMV, BK virus nephropathy, fungal, and opportunistic infections
Embryofetal toxicity: Significantly increased risk of miscarriage and birth defects (FDA boxed warning)
GI perforation/hemorrhage: Rare but serious; seek emergency care for severe abdominal pain, black stools, or coffee-ground vomit
Pure red cell aplasia: Rare bone marrow condition causing severe anemia
Know what you need? Skip the search.
Azathioprine (Imuran, Azasan)
Older antimetabolite immunosuppressant; was standard of care before mycophenolate; widely available, less expensive, but less effective at preventing acute rejection in early post-transplant period. Requires TPMT testing before use.
Sirolimus (Rapamune)
mTOR inhibitor; alternative for patients intolerant of mycophenolate GI side effects; has antitumor and antiviral properties; requires therapeutic drug monitoring and is not recommended immediately post-transplant due to wound healing concerns.
Everolimus (Zortress)
mTOR inhibitor approved for kidney transplant; used with reduced-dose tacrolimus; may help preserve kidney function; requires therapeutic drug monitoring.
Belatacept (Nulojix)
Costimulation blocker approved for kidney transplant; monthly IV infusion; may better preserve kidney function than calcineurin inhibitors; increased risk of PTLD in EBV-negative patients.
Prefer Mycophenolic Acid? We can find it.
Cholestyramine / bile acid sequestrants
majorSignificantly reduces MPA levels by interrupting enterohepatic recirculation; avoid combination or dose mycophenolate far apart from sequestrant
Azathioprine
majorBoth inhibit purine metabolism; additive myelotoxicity with no added benefit; never combine—use one or the other
Live vaccines (MMR, varicella, yellow fever, etc.)
majorContraindicated—immunosuppression can allow live vaccines to cause actual infection
Antacids (magnesium/aluminum: Maalox, Mylanta)
moderateReduces absorption of mycophenolate mofetil; separate doses by at least 2 hours
Sevelamer (Renagel, Renvela)
moderateDecreases MPA Cmax and AUC by 26–36%; administer mycophenolate 2 hours before sevelamer
Acyclovir / Valacyclovir / Ganciclovir / Valganciclovir
moderateCompete with MPAG for renal tubular secretion; both drug and MPAG levels can increase, especially with renal impairment
Hormonal contraceptives
moderateMycophenolate reduces contraceptive efficacy (levonorgestrel AUC reduced ~15%); use additional barrier method as second form of contraception
Cyclosporine
moderateCyclosporine inhibits MPA enterohepatic recirculation, reducing MPA AUC; patients switching from cyclosporine to tacrolimus may require monitoring of MPA levels
Oral activated charcoal
moderateCan significantly reduce MPA levels by binding bile acids and interrupting enterohepatic recirculation; avoid unless directed by physician
Mycophenolic acid—whether taken as Myfortic (mycophenolate sodium) or as the closely related mycophenolate mofetil (CellCept)—is one of the most important medications in transplant medicine. For millions of transplant recipients worldwide, it is a lifelong daily medication that stands between their immune system and their transplanted organ. Understanding how it works, what interactions to avoid, and how to manage its side effects can help patients stay safe and adherent for the long term.
Cost is manageable: with GoodRx or discount cards, generic mycophenolate mofetil can be obtained for as little as $18–$28 per month, and mycophenolate sodium for $40–$42 per month. Patient assistance programs, Medicare Part B coverage for eligible kidney transplant patients, and 340B pricing at qualifying transplant centers provide additional savings avenues for those who need them.
If you ever have difficulty finding your medication in stock, medfinder can help you quickly locate which pharmacies near you have your specific formulation and strength in stock, so you never have to risk missing a dose.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards